CliffBio
small molecule

RYALTRIS

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

Loss of exclusivityApril 2039latest FDA-listed patent expiry
CompanyGLENMARK SPECIALTY SA

Drug detail

Brand nameRYALTRIS
Active ingredientMOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE
Strength0.025MG/SPRAY;0.665MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalJanuary 2022
Marketing statusRX

Listed patents

PatentExpiresType
12303635April 2039substance, product
11679210September 2038product
10646500September 2034use U-3297
10548907September 2034use U-3297
11400101September 2034use U-3297
12064442September 2034use U-3297
10016443September 2034use U-3297
10517880September 2034product
9750754September 2034product
9078923September 2034product
10561672September 2034product
9370483September 2034product
10376526September 2034product
10765686September 2034use U-3295
9937189September 2034product
10758550September 2034use U-3296

More from GLENMARK SPECIALTY SA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RYALTRIS patent cliff — loss of exclusivity April 2039 | CliffBio